Company news

Rhythm Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

November 26, 2020

Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020

November 3, 2020

Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results

November 1, 2020

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology

October 29, 2020

Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America

October 27, 2020

Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

September 13, 2020

Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results

August 2, 2020

Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations

July 26, 2020

Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer

July 19, 2020

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism

July 15, 2020

Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities

June 30, 2020

Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers

June 23, 2020

Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities

May 12, 2020

Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results

May 3, 2020

Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations

March 29, 2020

Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome

March 17, 2020

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

March 1, 2020

Rhythm Pharmaceuticals Announces Leadership Transition

January 5, 2020

Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

December 4, 2019

Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019

November 3, 2019

Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

October 31, 2019

Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019

October 29, 2019

Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

October 17, 2019

Rhythm Pharmaceuticals Provides Update on Research and Development Programs

September 24, 2019

← Newer news releases

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 58 decks. Every deck is listed under its year.